Vincent Miles


  • LocationBoston
  • ExpertiseVenture Capital


Mary-Ellen Craig

Tel: + 781 466 8800

Vincent has more than 30 years of management experience in the biotechnology industry. He identifies and invests in new businesses and supports portfolio companies. Vincent is on the boards of IFM Therapeutics LLC and IFM Tre, having co-led Abingworth's investment in IFM Therapeutics, Inc (acquired by Bristol-Myers Squibb) and served on its Board. He is also a current member of the Boards of Hydra Biosciences and Personalis, and previously served on the boards of Chiasma, Dicerna Pharmaceuticals, Dynex Technologies, Magellan Diagnostics and PrimeraDx. Before joining Abingworth he was Senior Vice President, Business Development, of Alnylam Pharmaceuticals (a former Abingworth portfolio company).

Previously, Vincent was at Millennium Pharmaceuticals  where he held VP positions in business development, strategic planning and corporate communications. Earlier, he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held VP positions in business development and R&D at RiboGene and Pharmacia. He began his career in R&D at Amersham International. He has a BSc in Biochemistry and a PhD in Molecular Biology from University College London.